ASCO 2021: Telaglenastat plus cabozantinib for metastatic kidney cancer

Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, and RCC tumour cells tend to have high levels of an enzyme called glutaminase, a key enzyme for the metabolism of glutamine. Glutamine is an amino acid that is found in most proteins. It is a source of energy for cell growth. Telaglenastat is a […]

read more

CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]

read more

ENTRATA study of telaglenastat in combination with everolimus in patients with kidney cancer

In this video interview Dr Chung-Han Lee from Memorial Sloan Kettering Cancer Centre in the USA discusses the positive results from the phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with […]

read more

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

Results from the ENTRATA clinical trial to assess telaglenastat in combination with everolimus for patients with heavily pre-treated renal cell carcinoma were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Telaglenastat is a type of biological therapy called a glutaminase inhibitor that blocks the glutaminase enzyme, which is […]

read more

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more
Showing all 5 results